RxDoctor Payments Data

Anne Rowland

Adult Health · Frederick, MDNPI 1689840571

Payments from drug & device makers

$2,801in general payments, 2019–2025

Across 154 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$822
  • GSK$541
  • Boehringer Ingelheim$234
  • Electromed, Inc.$114
  • Axsome Therapeutics, Inc.$98
  • Inspire Medical Systems, Inc.$98
  • plus $895 from 18 others

What the payments were for

  • Food & beverage$2,801100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,801 in reported general payments places this provider in the 80th percentile of 542 adult health providers in Maryland.

See all adult health providers in Maryland

Medicare billing

Part B allowed, 2024
$18,991
Medicare patients
118
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter495$590,525
Breo ElliptaFluticasone/Vilanterol130$97,270
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr76$83,383
Spiriva RespimatTiotropium Bromide60$62,872
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$56,305
Incruse ElliptaUmeclidinium Bromide28$24,680
SymbicortBudesonide/Formoterol Fumarate51$24,129
Albuterol Sulfate HfaAlbuterol Sulfate668$23,039
Fluticasone-SalmeterolFluticasone Propion/Salmeterol83$17,256
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$16,392
Arnuity ElliptaFluticasone Furoate38$12,569
DuleraMometasone/Formoterol22$11,627
Combivent RespimatIpratropium/Albuterol Sulfate12$11,453
Advair HfaFluticasone Propion/Salmeterol14$11,102
Roflumilast37$8,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$541$808,427767 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$234$90,71788 claims
AstraZenecaBreztri Aerosphere, Symbicort$822$80,43587 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 542 adult health providers in Maryland.

Other adult health in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →